The value of booster vaccinations against diphtheria, tetanus, pertussis and poliomyelitis

Journal of Preventive Medicine and Hygiene

Volumn 49, Issue 1, 2008, Pages 47-54

  Gabutti, G ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Booster vaccinations; Diphtheria; Pertussis; Poliomyelitis; Tetanus

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HEMAGGLUTININ; INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE; PERTACTIN; PERTUSSIS VACCINE; POLIOBOOSTRIX; POLIOINFANRIX; TETANUS TOXOID;

ARTICLE; CLINICAL TRIAL; DIPHTHERIA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE PAIN; INJECTION SITE SWELLING; PERTUSSIS; POLIOMYELITIS; SINGLE DRUG DOSE; TETANUS; VACCINATION;

ADOLESCENT; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; DIPHTHERIA; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; INFANT; ITALY; PERTUSSIS VACCINE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; TETANUS; TETANUS TOXOID; WHOOPING COUGH;

EID: 48949095559     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Crovari P, Gabutti G. Basi epidemiologiche delle strategie vaccinali. Atti 36° Congresso Nazionale Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica: "L'Igienista nella gestione della salute dell'ambiente e delle comunità", 2° Volume: Relazioni, L'Igiene Moderna 1996;6:1385-401.
2. Crovari P, Gabutti G. Obiettivi e strategie delle vaccinazioni. In: Crovari P, Principi N, eds. Le vaccinazioni. Pisa: Pacini Editore 2000, pp. 51-68.
3. Gruppo di lavoro ICONA. ICONA 2003: indagine nazionale sulla copertura vaccinale infantile. Roma: Istituto Superiore di Sanità; Rapporti ISTISAN 2003;03/37:1-116.
4. Ciofi degli Atti ML, Rota MC, Bella A, Salmaso S. ICONA Study Group. Do changes in policy affect vaccine coverage levels? Results of a national study to evaluate childhood vaccination coverage and reasons for missed vaccination in Italy. Vaccine 2004;22:4351-7.
5. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR 2006;RR3:1-50.
6. Conferenza permanente per i rapporti tra lo Stato, Regioni e le Province Autonome di Trento e Bolzano. Determinazione 3 marzo 2005. Accordo ai sensi dell'art 4 del decreto legislativo 28 agosto 1997, n. 281, tra il Ministro della salute e i Presidenti delle regioni e delle province autonome, concernente il Nuovo Piano Nazionale Vaccini 2005-2007. GU n.86 del 14-04-2005-Suppl ordinario n. 63.
7. Decreto del Presidente della Repubblica 7 novembre 2001, n.464. Regolamento recante modalità di esecuzione delle rivaccinazioni antitetaniche, a norma dell'articolo 93, comma 2, della legge 23 dicembre 2000, n. 388. G.U. n. 7 del 9 gennaio 2002.
8. Gasparini R. Tetano. In: Crovari P, Principi N, eds. Le vaccinazioni. Pisa: Pacini Editore 2000, pp. 275-88.
9. Pedalino B, Cotter B, Ciofi degli Atti M, Mandolini D, Parroccini S, Salmaso S. Epidemiology of tetanus in Italy in years 1971-2000. EuroSurveill 2002;7:103-10.
10. Von Hunolstein C. Difterite. In: Crovari P, Principi N, eds. Le vaccinazioni. Pisa: Pacini Editore 2000, pp. 257-74.
11. Neal S, Efstratiou A. DIPNET- establishment of a dedicated surveillance network for diphtheria in Europe. EuroSurveill. 2007;12:Epub ahead of print. Available online: http://www. eurosurveillance.org/em/v12n12/ 1212-225.asp.
12. Bergamini M, Comodo N, Gasparini R, Gabutti G, Fabrizi P, Severini R, et al. Prevalence of diphtheria toxin antibodies in human sera from a cross-section of the Italian population. Vaccine 1999;17:286-90.
13. Edmunds WJ, Pebody RG, Aggerback H, Baron S, Berbers G, Conyn-van Spaendonck MA, et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European SeroEpidemiology Network. Epidemiol Infect 2000;125:113-25.
14. Galazka AM, Robertson SE. Immunization against diphtheria with special emphasis on immunization of adults. Vaccine 1996;14:845-57.
15. Hasselhorn HM, Nubling M, Tiller FW, Hofmann F. Factors influencing immunity against diphtheria in adults. Vaccine 1998;16:70-5.
16. Christenson B, Hellstrom U, Sylvan SP, Henriksson L, Granstrom M. Impact of a vaccination campaign on adult immunity to diphtheria. Vaccine 2001;19:1133-40.
17. Vitek CR. Diphtheria. Curr Top Microbiol Immunol 2006;304:71-94.
18. Pastore Celentano L, Massari M, Paramatti D, Salmaso S, Tozzi AE, on behalf of the EUVAC-NET Group. Resurgence of Pertussis in Europe. Ped Infect Dis J 2005;24:761-5.
19. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-82.
20. Greco D, Ciofi degli Atti ML. Pertosse. su: In: Crovari P, Principi N, eds. Le vaccinazioni. Pisa: Pacini Editore 2000, pp. 289-304.
21. Rota MC, D'Ancona F, Massari M, Mandolini D, Giammnaco A, Carbonari P, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005;23:5299-305.
22. Mills KHG. Immunity to Bordetella pertussis. MicrobInfect 2001;3:655-77.
23. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis 2004;190:535-44.
24. Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr 2008;167:133-9.
25. Campins-Martí M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, et al. International Consensus Group on Pertussis Immunisation. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001;20:641-6.
26. Wirsing von Konig CH, Riffelmann M. Pertussis: an old disease in new clothes. EuroSurv 2007;12 (Epub ahead of print). Available online: http://www.eurosurveillance.org/em/v12n09/1209-221.asp.
27. Gabutti G, Bergamini M, Bonanni P, Guido M, Fenoglio D, Giammanco A, et al. Assessment of humoral and cell mediated immunity against Bordetella pertussis in adolescent, adult and senior subjects in Italy. Epidemiol Infect 2008:1-9 (Epub ahead of print).
28. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007;25:2634-42.
29. Patti AM, Santi AL, Fiore L, Vellucci L, De Stefano D, Bellelli E, et al. Environmental surveillance of poliovirus in Italy: pilot study. Ann Ig 2003;15:97-105.
30. Majori S, Baldo V, Poli A, Riolfatti M, Alberino F, Bonello C, et al. Immunity to poliovirus among children and the elderly in north-east Italy. J Prev Med Hyg 2006;47:12-5.
31. WHO. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication. Geneva 27-28 November 2007. Wkly Epidemiol Rec 2008;83:25-35.
32. WHO. www.who.mt/immunization_monitoring/en/globalsummary/diseaseresult. cfm.
33. Gabutti G. Stato dell'arte nelle diverse realtà italiane: le basi razionali e la strategia comune di richiamo vaccinale. J Prev Med Hyg 2004;45S1:11-3.
34. Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid coniugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 1999;28:995-1001.
35. Gabutti G. Pertosse: epidemiologia, immunitá e razionale per il richiamo vaccinale negli adolescenti. J Prev Med Hyg 2002;43:14-9.
36. Meriste S, Tamm E, Willems P, Lutsar L. Safety and immunogenicity of combined DTPa-IPV vaccine for primary and booster vaccination. Scand Infect Dis J 1999;31:587-91.
37. Jacquet JM, Begué P, Grimpel E, Reinert P, Sandbu S, Silfverdal SA, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 2006;24:2440-8.
38. th Annual Meeting ESPID 2002.
39. st Annual Meeting ESPID 2003, p. 247.
40. Wolter J, Grimpel E, Tregnaghi M, Vergara R, Von Sonnenburg F, Abitbol V, et al. Boostrix Polio: a new combined vaccine to fulfill emerging needs for pertussis vaccination of older-age-groups. Tampere, Finland: 22th Annual Meeting ESPID 2004, p. 319.
41. Vergara R, Tregnaghi M, Ussher J, Navarro S, Ruttimann R, Potin M, et al. Reduced-antigen-content-diphtheria-tetanus-acellular pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Fed 2005;164:377-82.
42. Grimpel E. Von Sonnenburg F, Ranger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diptheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005;23:3657-67.
43. Cherry JD. Pertussis vaccines for adolescents and adults. Pediatrics 2006;116:755-6.
44. CDC. General recommendations on immunization. Recommendations of the Advisory Committee on immunization practices (ACIP). MMWR 2006;55:1-56.
45. CDC. Preventing tetanus, diphtheria and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization practices (ACIP) and Recommendations of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among Health-care personnel. MMWR 2006;55:1-44.
46. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention. New opportunities through adult vaccination. Am J Prev Med 2007;32:177-85.
47. Ciofi degli Atti ML, Salmaso S, Cotter B, Gallo G, Alfarone G, Pinto A, et al. Reactogenicity and immunogenicity of adult vs. paediatric diphtheria and tetanus booster dose at 6 years of age. Vaccine 2002;20:74-9.
48. st Annual Meetng ESPID 2003.
49. Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, et al. Reactogenicity and immunogenicity of reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003;21:4194-200.
50. Di Pasquale A, Wolter J, Schuerman L. Prevenzione della pertosse nell'adolescente e nell'adulto: ruolo di un vaccina acellulare combinato a ridotto contenuto antigenico difterite-tetanopertosse acellular e (dTap). J Prev Med Hyg 2005:46:33-40.
51. Edelman K, He Q, Makinen J, Sahlberg A, Haanpera M, Schuerman L, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007;44:1271-7.
52. Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter J, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004;23:336-42.